| Year |
Citation |
Score |
| 1939 |
Späth E, Bose PK, Dobrovolny E, Mookerjee A. Isolierung von Xanthyletin aus Luvunga scandens Ham European Journal of Inorganic Chemistry. 72: 1450-1452. DOI: 10.1002/Cber.19390720721 |
0.292 |
|
| 1939 |
Späth E, Bose PK, Matzke J, Guha NC. Die Cumarine von Seseli indicum und die Konstitution des Seselins European Journal of Inorganic Chemistry. 72: 821-830. DOI: 10.1002/Cber.19390720427 |
0.359 |
|
| 1937 |
Späth E, Bose PK, Gruber W, Guha NC. Über das Marmelosin (XXVIII. Mitteil. über natürliche Cumarine) European Journal of Inorganic Chemistry. 70: 1021-1023. DOI: 10.1002/Cber.19370700530 |
0.256 |
|
| 1937 |
Späth E, Bose PK, Schläger J. Konstitution und Synthese von Ayapin (XXVI. Mitteil. über natürliche Cumarine) European Journal of Inorganic Chemistry. 70: 702-704. DOI: 10.1002/Cber.19370700421 |
0.337 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2013 |
Gopinath VS, Pinjari J, Dere RT, Verma A, Vishwakarma P, Shivahare R, Moger M, Kumar Goud PS, Ramanathan V, Bose P, Rao MV, Gupta S, Puri SK, Launay D, Martin D. Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents. European Journal of Medicinal Chemistry. 69: 527-36. PMID 24095747 DOI: 10.1016/j.ejmech.2013.08.028 |
0.091 |
|
| 1999 |
Costantino L, Rastelli G, Gamberini MC, Vinson JA, Bose P, Iannone A, Staffieri M, Antolini L, Del Corso A, Mura U, Albasini A. 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. Journal of Medicinal Chemistry. 42: 1881-93. PMID 10354396 DOI: 10.1021/jm980441h |
0.075 |
|
| 1988 |
Vinson JA, Bose P. Comparative bioavailability to humans of ascorbic acid alone or in a citrus extract. The American Journal of Clinical Nutrition. 48: 601-4. PMID 3414575 |
0.022 |
|
| 2014 |
Bose P, Batalo MS, Holkova B, Grant S. Bortezomib for the treatment of non-Hodgkin's lymphoma. Expert Opinion On Pharmacotherapy. 15: 2443-59. PMID 25263936 DOI: 10.1517/14656566.2014.965142 |
0.019 |
|
| 2012 |
Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Douglas Figg W, Karp JE, Koc ON, Cooper BW, Luger SM, et al. Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. Cancer Chemotherapy and Pharmacology. 69: 1657-67. PMID 22349810 DOI: 10.1007/S00280-012-1839-5 |
0.017 |
|
| 2015 |
Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann MA, Xi L, Raffeld M, Zhao X, Wan W, et al. A Phase 2 Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26446942 DOI: 10.1158/1078-0432.Ccr-15-1076 |
0.014 |
|
| 2014 |
Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5652-62. PMID 25248382 DOI: 10.1158/1078-0432.Ccr-14-0805 |
0.01 |
|
| 2002 |
Gaus G, Demir-Weusten AY, Schmitz U, Bose P, Kaufmann P, Huppertz B, Frank HG. Extracellular pH modulates the secretion of fibronectin isoforms by human trophoblast. Acta Histochemica. 104: 51-63. PMID 11993851 DOI: 10.1078/0065-1281-00631 |
0.01 |
|
| Hide low-probability matches. |